JP2022546550A5 - - Google Patents

Info

Publication number
JP2022546550A5
JP2022546550A5 JP2022514172A JP2022514172A JP2022546550A5 JP 2022546550 A5 JP2022546550 A5 JP 2022546550A5 JP 2022514172 A JP2022514172 A JP 2022514172A JP 2022514172 A JP2022514172 A JP 2022514172A JP 2022546550 A5 JP2022546550 A5 JP 2022546550A5
Authority
JP
Japan
Prior art keywords
approximately
subject
cbs
thcy
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022514172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546550A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/049156 external-priority patent/WO2021046190A1/en
Publication of JP2022546550A publication Critical patent/JP2022546550A/ja
Publication of JP2022546550A5 publication Critical patent/JP2022546550A5/ja
Priority to JP2025130469A priority Critical patent/JP2025183204A/ja
Pending legal-status Critical Current

Links

JP2022514172A 2019-09-03 2020-09-03 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法 Pending JP2022546550A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025130469A JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962895230P 2019-09-03 2019-09-03
US62/895,230 2019-09-03
US202062983862P 2020-03-02 2020-03-02
US62/983,862 2020-03-02
PCT/US2020/049156 WO2021046190A1 (en) 2019-09-03 2020-09-03 Cystathionine beta-synthase enzyme therapy for treatment of elevated homocysteine levels

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025130469A Division JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Publications (2)

Publication Number Publication Date
JP2022546550A JP2022546550A (ja) 2022-11-04
JP2022546550A5 true JP2022546550A5 (cg-RX-API-DMAC7.html) 2023-09-07

Family

ID=74852233

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022514172A Pending JP2022546550A (ja) 2019-09-03 2020-09-03 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法
JP2025130469A Pending JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025130469A Pending JP2025183204A (ja) 2019-09-03 2025-08-05 上昇したホモシステインレベルを処置するためのシスタチオニンベータ合成酵素による酵素療法

Country Status (11)

Country Link
US (1) US20220290116A1 (cg-RX-API-DMAC7.html)
EP (1) EP4025243A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022546550A (cg-RX-API-DMAC7.html)
KR (1) KR20220091464A (cg-RX-API-DMAC7.html)
CN (1) CN114630673A (cg-RX-API-DMAC7.html)
AU (1) AU2020343314A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003539A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152379A1 (cg-RX-API-DMAC7.html)
IL (1) IL290685A (cg-RX-API-DMAC7.html)
MX (1) MX2022002571A (cg-RX-API-DMAC7.html)
WO (1) WO2021046190A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675678B2 (en) 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
DK3998067T3 (da) 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
MX2021015966A (es) 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034318B2 (en) * 2011-08-30 2015-05-19 The Regents Of The University Of Colorado, A Body Corporate Chemically modified cystathionine beta-synthase enzyme for treatment of homocystinuria
US9675678B2 (en) * 2013-01-29 2017-06-13 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for treatment of homocystinuria
DK3998067T3 (da) * 2015-11-09 2024-10-28 Univ Colorado Regents Sammensætninger og fremgangsmåder til behandling af homocystinuri
CA3059592A1 (en) * 2017-04-17 2018-10-25 The Regents Of The University Of Colorado, A Body Corporate Optimization of enzyme replacement therapy for treatment of homocystinuria
MX2021015966A (es) * 2019-06-26 2022-04-06 Travere Therapeutics Switzerland Gmbh Producto farmacológico para terapia enzimática para el tratamiento de la homocistinuria.

Similar Documents

Publication Publication Date Title
US12558324B2 (en) Application of R-ketamine and salt thereof as pharmaceuticals
JP5363152B2 (ja) グリシン捕捉性アンタゴニストを用いる拒絶性および認知性精神分裂病症候群の処置
ES2284660T3 (es) Composicion que contiene un antiofolato y un agente que rebaja el acido metilmalonico.
Guaraldi et al. An open trial of methyltetrahydrofolate in elderly depressed patients
Sessa et al. Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
CN111417391B (zh) 用于抑制肿瘤生长的材料和方法
CN112867512A (zh) 联合疗法
KR20050044587A (ko) B형 간염 바이러스 감염 치료용 포스포네이트뉴클레오타이드 유사체의 용도
JP2018530578A (ja) 組み合せ抗細菌組成物および短期抗細菌レジメン
Wei et al. Folate/vitamin-B12 prevents chronic hyperhomocysteinemia-induced tau hyperphosphorylation and memory deficits in aged rats
JP6966840B2 (ja) 神経変性疾患の改善用医薬
WO2017151723A1 (en) Cobalamin compositions and use thereof for improving cognitive function
JP6867142B2 (ja) パーキンソン症状改善用医薬
US10172857B2 (en) Boosting the effect of methotrexate through the combined use with lipophilic statins
JP2017533967A (ja) システアミン組成物を用いるハンチントン病の処置方法
TW202247843A (zh) 醫藥組合物治療肺癌之用途
JP2006508118A5 (cg-RX-API-DMAC7.html)
Undas et al. Homocysteine in adult patients with cardiovascular disease: is it clinically relevant in 2025? A tribute to Hieronim Jakubowski (1946-2025)
Hanauske et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer
CN115175678B (zh) 使用btk抑制剂及其组合治疗dlbcl的方法
JP2024016228A (ja) アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
Wilks et al. First case of foot drop associated with capecitabine in a patient with thymidylate synthase polymorphism
US20210038676A1 (en) Copper complexes for treatment of neurodegenerative disorders
KR20220024434A (ko) 신경퇴행성 장애를 치료하는 방법
JP2007523827A (ja) 混合性白血病遺伝子の再構成を伴う急性リンパ芽球性白血病の処置方法